person · Reporting owner
Fairmount Healthcare Fund II L.P.
Disclosed activity across 9 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Director · 10% owner | July 16, 2026 | July 20, 2026 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director · 10% owner | March 23, 2026 | March 25, 2026 |
| Jade Biosciences, Inc.JBIO · Entity 4757 | Director · 10% owner | June 09, 2026 | June 11, 2026 |
| Korsana Biosciences, Inc.KRSA · Entity 7698 | Director · 10% owner | September 09, 2026 | September 10, 2026 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director · 10% owner | July 01, 2026 | July 02, 2026 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director | June 23, 2026 | June 24, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director · 10% owner | May 11, 2026 | May 13, 2026 |
| Zenas BioPharma, Inc.ZBIO · Entity 275 | Director | March 31, 2026 | April 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date July 16, 2026 · Filed July 20, 2026
Jointly reported with Fairmount Funds Management LLC, Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II L.P. | 3,601,316 |
Reported balance
After 2026-07-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-07-16 · Purchase · Acquired 853,450 · Balance 3,601,316 F1: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Pre-Funded Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Fairmount Healthcare Fund II L.P. | 2,294,037 |
Reported balance
After 2026-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-16 · Purchase · Acquired 525,897 · Balance 2,294,037 F2: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise. F1: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise.
Damora Therapeutics, Inc.
Report date March 23, 2026 · Filed March 25, 2026
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Co-Invest V L.P., Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2036-03-23 | IndirectBy: Peter Harwin | 37,313 |
Reported balance
After 2026-03-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-23 · Grant · Acquired 37,313 · Balance 37,313 F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest V L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest V L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Jade Biosciences, Inc.
Report date June 09, 2026 · Filed June 11, 2026
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Co-Invest IV L.P., Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2036-06-08 | Direct | 34,843 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 34,843 · Balance 34,843 F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to Tomas Kiselak's continued service to the Issuer. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest IV L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to Tomas Kiselak's continued service to the Issuer.
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest IV L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Korsana Biosciences, Inc.
Report date September 09, 2026 · Filed September 10, 2026
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Co-Invest VI L.P., Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.20 · Expires 2036-09-09 | IndirectBy: Tomas Kiselak | 48,445 |
Reported balance
After 2026-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-09 · Grant · Acquired 48,445 · Balance 48,445 F1: This option represents a right to purchase 48,445 shares of the Issuer's common stock. This option will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II") and Fairmount Healthcare Co-Invest VI L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 48,445 shares of the Issuer's common stock. This option will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II") and Fairmount Healthcare Co-Invest VI L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Oruka Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Co-Invest III L.P., Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II L.P. | 1,131,954 |
Last balance in matching sequence
After 2026-07-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-01 · Conversion · Acquired 3,553,410 · Balance 4,685,364 F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Row 2 · 2026-07-01 · Sale · Disposed 3,553,410 · Balance 1,131,954 F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II L.P. | 94,497 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Conversion · Disposed 42,641 · Balance 94,497 F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Co-Invest III L.P. | 2,573,308 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,573,308 F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Spyre Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
Jointly reported with Fairmount Funds Management LLC, Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II L.P. | 0 |
Last balance in matching sequence
After 2026-06-23 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-06-23 · Conversion · Acquired 666,680 · Balance 4,684,781 F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Row 2 · 2026-06-23 · Sale · Disposed 4,684,781 · Balance 0 F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectFairmount Healthcare Fund II LP | 0 |
Reported balance
After 2026-06-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-23 · Conversion · Disposed 16,667 · Balance 0 F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Tomas Kiselak | 406,038 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 406,038 |
| Common StockSEC Table I · non-derivative | IndirectBy Peter Harwin | 406,038 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 406,038 |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectFairmount Healthcare Fund II LP | 346,045 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 346,045 F3: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock.
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
Viridian Therapeutics, Inc.\DE
Report date May 11, 2026 · Filed May 13, 2026
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II L.P. | 5,090,928 |
Reported balance
After 2026-05-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-05-11 · Purchase · Acquired 1,176,470 · Balance 5,090,928 F1: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Zenas BioPharma, Inc.
Report date March 31, 2026 · Filed April 01, 2026
Jointly reported with Fairmount Funds Management LLC, Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II L.P. | 2,359,025 |
Reported balance
After 2026-03-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-03-31 · Purchase · Acquired 150,000 · Balance 2,359,025 F1: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Jointly reported with Fairmount Funds Management LLC, Kiselak Tomas, Harwin Peter Evan
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II LP | 0 |
Reported balance
After 2026-09-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 340,855 · Balance 0 F1: Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration"). F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Tomas Kiselak | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 51,166 · Balance 0 F1: Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Peter Harwin | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 51,166 · Balance 0 F1: Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration"). |
| Non-Voting Common StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II LP | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 6,743,321 · Balance 0 F3: The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may have been changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not have exceeded 19.99%. F1: Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration"). F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2033-07-13 | IndirectBy Tomas Kiselak | 0 |
Reported balance
After 2026-09-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-03 · Disposition to issuer · Disposed 47,758 · Balance 0 F5: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option. F4: As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the "Merger"), or became fully vested in connection with the Merger. F6: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.85 · Expires 2034-06-05 | IndirectBy Tomas Kiselak | 0 |
Reported balance
After 2026-09-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-03 · Disposition to issuer · Disposed 10,370 · Balance 0 F5: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option. F4: As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the "Merger"), or became fully vested in connection with the Merger. F6: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.66 · Expires 2035-06-17 | IndirectBy Tomas Kiselak | 0 |
Reported balance
After 2026-09-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-03 · Disposition to issuer · Disposed 14,461 · Balance 0 F5: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option. F4: As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the "Merger"), or became fully vested in connection with the Merger. F6: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2036-06-09 | IndirectBy Tomas Kiselak | 0 |
Reported balance
After 2026-09-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-03 · Disposition to issuer · Disposed 7,657 · Balance 0 F5: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option. F4: As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the "Merger"), or became fully vested in connection with the Merger. F6: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration").
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3: The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may have been changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not have exceeded 19.99%.
F4: As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the "Merger"), or became fully vested in connection with the Merger.
F5: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option.
F6: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2023 Filed Jul 17, 2023 20:00 UTC | Apogee Therapeutics, Inc. APGE · Entity 1939 | PurchaseCommon Stock | 55,913 | $17.00 | $950,521.00 |
DisclosureSEC source: 0001104659-23-081729 · tm2321456-6_4seq1.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director Fairmount Healthcare Co-Invest II L.P. · CIK 0001982189 · Director Kiselak Tomas · CIK 0001830177 · Director Harwin Peter Evan · CIK 0001663607 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund LP Disclosed balance after: 55,913 F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 425,531 | $23.50 | $9,999,978.50 |
DisclosureSEC source: 0001104659-22-092992 · tm2224209-1_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · 10% owner Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,363,764 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 09:30 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 909,000 | $11.00 | $9,999,000.00 |
DisclosureSEC source: 0000899243-21-037255 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 938,233 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 28,843 | $465.96 | $13,439,684.28 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 111,192 Underlying: Common Stock · 28,483,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 5,494 | $465.96 | $2,559,984.24 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 21,999 Underlying: Common Stock · 5,494,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 82,349 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 82,349 Underlying: Common Stock · 82,349,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 16,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 16,505 Underlying: Common Stock · 16,505,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherCommon Stock | 438,502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 438,502 F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherCommon Stock | 87,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 87,891 F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.